Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prostate Cancer Screening: a Pilot Study
Sponsor: Fondazione del Piemonte per l'Oncologia
Summary
Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.
Official title: Prostate Cancer Screening With PSA, Risk Calculator and Multiparametric MRI: a Pilot Study
Key Details
Gender
MALE
Age Range
55 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
4500
Start Date
2025-02-17
Completion Date
2026-06-30
Last Updated
2026-03-05
Healthy Volunteers
No
Conditions
Interventions
Urology visit with Risk Calculator and MRI
Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
Locations (1)
Fondazione del Piemonte per l'Oncologia
Candiolo, Italy, Italy